|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
Answering questions from the Biotech Mailbag on FLXN and SGYP.
AstraZeneca shares, meanwhile, were less-than-moved by the news.